Immix Biopharma, Inc. IMMX
Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor cell therapy ("CAR-T")
in light chain (AL) Amyloidosis and other serious diseases. Our lead cell therapy candidate is CAR-T NXC-201 ("NXC-201"),
currently being evaluated in our ongoing United States Phase 1b/2 NEXICART-2 (NCT06097832) clinical trial and an ex-U.S. phase 1b/2a
NEXICART-1 (NCT04720313) clinical trial. NEXICART-2 is expected to enroll 40 patients, with final readout and Biologics License Application
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D | $16.3M | $11.3M | $8.7M | $4.2M | $126.5K | $248.1K | — |
| SG&A | $13.7M | $11.4M | $7.4M | $4.0M | $1.2M | $205.7K | — |
| Total operating expenses | $30.0M | $22.7M | $16.1M | $8.2M | $1.4M | $453.9K | — |
| Operating income | -$30.0M | -$22.7M | -$16.1M | -$8.2M | -$1.4M | -$453.9K | — |
| Interest expense | — | — | — | $497 | $179.9K | $102.0K | — |
| Pre-tax income | -$29.4M | -$21.7M | -$15.6M | -$8.2M | -$24.4M | -$1.1M | — |
| Income tax | $37.7K | $41.0K | $26.4K | $10.3K | $6.0K | $17.5K | — |
| Net income | -$29.4M | -$21.6M | -$15.4M | -$8.2M | -$24.4M | -$1.1M | — |
| EPS, basic | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | — | — |
| EPS, diluted | -0.89 | -0.76 | -0.89 | -0.59 | -6.64 | -0.34 | — |
| Shares, diluted (wtd. avg.) | 33.0M | 28.3M | 17.3M | 13.9M | 3.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $93.9M | $17.7M | $17.5M | $13.4M | $17.6M | $391.1K | — |
| Short-term investments | $6.5M | — | — | — | — | — | — |
| Total current assets | $101.2M | $20.2M | $19.8M | $14.9M | $18.2M | $532.2K | — |
| Property, plant and equipment | $2.5M | $1.7M | $50.2K | $3.6K | $5.7K | $7.4K | — |
| Total assets | $104.8M | $22.9M | $19.9M | $14.9M | $18.2M | $539.6K | — |
| Accounts payable | $5.4M | $5.4M | $1.4M | $143.1K | $142.9K | $252.3K | — |
| Total current liabilities | $10.1M | $8.7M | $3.7M | $1.3M | $202.0K | $5.3M | — |
| Total liabilities | $11.0M | $9.7M | $3.7M | $1.7M | $202.0K | $5.3M | — |
| Retained earnings | -$104.5M | -$75.0M | -$53.4M | -$38.0M | -$29.8M | -$5.4M | — |
| Total equity | $93.8M | $13.3M | $16.2M | $13.2M | $18.0M | -$4.7M | -$3.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.9M | -$14.6M | -$11.4M | -$7.4M | -$1.6M | -$404.7K | — |
| Depreciation and amortisation | $245.7K | $32.9K | $5.5K | $2.1K | $2.5K | $2.3K | — |
| Stock-based compensation | $2.4M | $3.0M | $2.6M | $624.1K | $219.0K | — | — |
| Capital expenditure | $732.9K | $1.2M | $52.1K | — | $802 | — | — |
| Investing cash flow | -$7.2M | -$1.2M | -$52.1K | — | -$802 | — | — |
| Financing cash flow | $107.4M | $15.9M | $15.5M | $3.2M | $18.8M | — | — |
| Buybacks | — | — | — | $100.0K | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-013298.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — |
| Net income | — | -$1.1M | -$24.4M | -$8.2M | -$15.4M | -$21.6M | -$29.4M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Other event Item 8.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |